Instructing the enrolling clerk of the House to make corrections to H.B. No. 46.
The impact of H.C.R. No. 171 is primarily administrative, as it ensures that the technical corrections are made to House Bill No. 46. This aligns the legislation with intended regulatory standards regarding low-THC cannabis usage, particularly for medical purposes. By correcting these specifics, it reinforces the safety and efficacy of cannabis products prescribed for pulmonary use, adhering to state laws governing THC content.
H.C.R. No. 171 is a House Concurrent Resolution that addresses a technical error in House Bill No. 46, which pertains to regulations surrounding low-THC cannabis. The resolution instructs the enrolling clerk of the House of Representatives to make necessary corrections in the enrolled version of House Bill No. 46. Specifically, the resolution indicates the removal of a provision that previously allowed certain low-THC cannabis to contain more than one percent by weight of tetrahydrocannabinols in dosage units intended for pulmonary inhalation.
There may be points of contention regarding the implications of this resolution. While the resolution is framed as a technical fix, stakeholders in the medical cannabis community could argue about the broader implications this may have on access and regulation of low-THC cannabis products. Moreover, debates may arise concerning the adequacy of regulatory measures in protecting public health while facilitating access for individuals requiring medical cannabis treatment.